Brief: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
21/02/2024 14:20
Feb 21 (Reuters) - Kazia Therapeutics Ltd KZIA.O :
* KAZIA THERAPEUTICS REPORTS EARLY CONCLUSION OF CLINICAL
TRIAL
AFTER REACHING PRIMARY ENDPOINT
* KAZIA THERAPEUTICS LTD - PAXALISIB PLUS RADIOTHERAPY DATA
SHOWS
PROMISE FOR TREATING PATIENTS WITH PI3K PATHWAY MUTATION BRAIN
METASTASES
* KAZIA THERAPEUTICS: PREPARING TO ENGAGE WITH FDA TO
DISCUSS DATA
AND SEEK GUIDANCE ON CONDUCT OF A PIVOTAL REGISTRATION STUDY
Source text for Eikon: ID:nPnbvbHy0a
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering